An Ethical Overview of the CRISPR-Based Elimination of Anopheles gambiae to Combat Malaria.


Journal

Journal of bioethical inquiry
ISSN: 1872-4353
Titre abrégé: J Bioeth Inq
Pays: Netherlands
ID NLM: 101250741

Informations de publication

Date de publication:
09 2022
Historique:
received: 13 08 2021
accepted: 02 12 2021
pubmed: 18 2 2022
medline: 14 9 2022
entrez: 17 2 2022
Statut: ppublish

Résumé

Approximately a quarter of a billion people around the world suffer from malaria each year. Most cases are located in sub-Saharan Africa where Anopheles gambiae mosquitoes are the principal vectors of this public health problem. With the use of CRISPR-based gene drives, the population of mosquitoes can be modified, eventually causing their extinction. First, we discuss the moral status of the organism and argue that using genetically modified mosquitoes to combat malaria should not be abandoned based on some moral value of A. gambiae. Secondly, we argue that environmental impact studies should be performed to obtain an accurate account of the possible effects of a potential eradication of the organism. However, the risks from the purposeful extinction of A. gambiae should not overtake the benefits of eradicating malaria and risk assessments should be used to determine acceptable risks. Thirdly, we argue that the eventual release of the genetically modified mosquitoes will depend on transparency, community involvement, and cooperation between different nations.

Identifiants

pubmed: 35175513
doi: 10.1007/s11673-022-10172-0
pii: 10.1007/s11673-022-10172-0
pmc: PMC9463432
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

371-380

Informations de copyright

© 2022. Journal of Bioethical Inquiry Pty Ltd.

Références

Pathog Glob Health. 2019 Jul;113(5):238-245
pubmed: 31549925
PLoS Med. 2016 Jan 19;13(1):e1001942
pubmed: 26783752
EFSA J. 2020 Nov 12;18(11):e06297
pubmed: 33209154
Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8275-8282
pubmed: 30940750
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3286-91
pubmed: 24596427
Trop Med Int Health. 2003 Jun;8(6):512-7
pubmed: 12791056
Nature. 2010 Jul 22;466(7305):432-4
pubmed: 20651669
Lancet. 2013 Sep 14;382(9896):963-72
pubmed: 23790353
Insect Biochem Mol Biol. 2013 Apr;43(4):407-16
pubmed: 23123179
PLoS Genet. 2017 Oct 4;13(10):e1007039
pubmed: 28976972
BMJ Glob Health. 2017 Aug 19;2(3):e000396
pubmed: 29082018
Lancet. 2019 Sep 21;394(10203):1056-1112
pubmed: 31511196
Nat Biotechnol. 2012 Sep;30(9):828-30
pubmed: 22965050
PLoS One. 2019 Jan 24;14(1):e0211205
pubmed: 30677102
Nature. 2019 Jul;571(7764):160-162
pubmed: 31289403
Infect Drug Resist. 2019 Jan 14;12:229-234
pubmed: 30666138
Dev World Bioeth. 2018 Jun;18(2):135-143
pubmed: 28470752
Malar J. 2002 Nov 15;1:14
pubmed: 12495438
Med Vet Entomol. 2019 Mar;33(1):1-15
pubmed: 30044507
Mol Cell. 2020 Oct 15;80(2):246-262.e4
pubmed: 32949493
Res Policy. 2020 Apr;49(3):103917
pubmed: 32255861
J Med Ethics. 2016 Sep;42(9):578-81
pubmed: 27118691
PLoS Negl Trop Dis. 2015 Jul 02;9(7):e0003864
pubmed: 26135160
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7692-7697
pubmed: 30642954
Trop Med Int Health. 2003 Aug;8(8):685-92
pubmed: 12869089
Curr Biol. 2015 May 18;25(10):R431-8
pubmed: 25989087
Lancet Infect Dis. 2004 Jun;4(6):327-36
pubmed: 15172341
JAMA. 2011 Mar 2;305(9):930-1
pubmed: 21364141
Malar J. 2016 Dec 1;15(1):578
pubmed: 27903266
Nat Biotechnol. 2018 Dec;36(11):1062-1066
pubmed: 30247490
Nat Ecol Evol. 2018 Sep;2(9):1458-1467
pubmed: 30061564
Nat Biotechnol. 2010 Sep;28(9):896-7
pubmed: 20829820
PLoS One. 2018 Feb 23;13(2):e0193378
pubmed: 29474454
Genetics. 2017 Feb;205(2):827-841
pubmed: 27941126
Elife. 2014 Jul 17;3:
pubmed: 25035423
Pathog Glob Health. 2017 Dec;111(8):412-423
pubmed: 29457956
Trop Med Int Health. 2000 Mar;5(3):179-84
pubmed: 10747280

Auteurs

India Jane Wise (IJ)

Centre for Biomedical Ethics and Law (CBMER), Department of Public Health and Primary Care, Faculty of Medicine, KU Leuven, Kapucijnenvoer 35 Box, 7001 3000, Leuven, Belgium. indiajanewise@gmail.com.

Pascal Borry (P)

Centre for Biomedical Ethics and Law (CBMER), Department of Public Health and Primary Care, Faculty of Medicine, KU Leuven, Kapucijnenvoer 35 Box, 7001 3000, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH